Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myeloma.

Interestingly, the number of previous lines of treatment positively correlated with HR cytogenetic ( Figure 4 D; P < .001) and EMD ( Figure 4 E; P < .01) and showed a trend toward increased numbers of CAR+ T EM cells detected in HBI0101 FP ( Figure 4 F; P = .08).

also in 53,322 other papers